Red light therapy (photobiomodulation)

Red and near-infrared light is absorbed by cytochrome c oxidase in mitochondria, increasing ATP production and reducing oxidative stress. Human oocytes contain 100,000–600,000 mitochondria — more than any other cell — making them especially responsive.

Female fertility: In 701 women who had failed ART (avg age 39, avg 9 years infertile), 830 nm laser achieved a 22.3% pregnancy rate with 79 live deliveries — with zero adverse events (Ohshiro 2012). A 2024 case series using red+NIR during the follicular phase improved AMH, endometrial thickness, and hormonal profiles. Animal studies show restored mitochondrial membrane potential and enhanced fertilization capacity in aging oocytes.

Male fertility: Multiple studies confirm PBM increases sperm motility — up to 100% improvement with combined wavelengths (Ahmed 2024). DNA integrity is unaffected at therapeutic doses. Critical: dose matters — the response is biphasic (Arndt-Schulz curve). Lower doses (0.6 J/cm2) outperform higher ones. Use LED devices, not laser, for testicular application to avoid thermal damage.

Timing: Female protocols should focus on the follicular phase. Start 90+ days before planned conception (oocyte development from primordial follicle to ovulation takes ~90 days). Discontinue abdominal exposure once pregnancy is confirmed.

Evidence grade: Mechanistically compelling (mitochondrial pathway well-established), consistent preclinical data, but clinical evidence remains at the case-series level. Only one small RCT exists for female fertility (n=30, underpowered). A rigorous trial (HELIOS, Columbia University) is recruiting. Consider this an adjunctive approach, not a replacement for established treatments.